<!--*****************************************************************************************
* Program Name  : index.html
* Project       : BOS-580-201
* Programmer    : Mark Woodruff
* Creation Date : 2021-09-23 (copied to BOS-580-201 from BOS172738-01)
* Description   : create landing page for patient profiles
*
* Revision History 
* Date       By            Description of Change
******************************************************************************************-->

<!DOCTYPE html>
<html lang="en">

	<head>
		<meta charset="utf-8" content="IE=edge">
		<title> Patient Profiles </title>
		<link rel="stylesheet" href="..\programs\assets\stylesheets\main.css?Rev=202104121030">
		<link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Lato:100,150,200,250,300,350,400,450,500,550,600,650,700,750,800,850,900">
	</head>

	<body>

		<!------------>
		<!-- HEADER -->
		<!------------>
		<header class="header-container">
			<div class="header-header">
				<a class="logo" href="https://bostonpharmaceuticals.sharepoint.com/SitePages/HAL-9000.aspx">
					<img src="..\programs\assets\images\bp-logo-white.png" alt="Company Logo">
				</a>

				<div class="header-right">
					<h2 class="tagline">Patient Profiles</h2>
                          
					<nav class="nav">                                    
						<a href=".\index.html">studies</a>
						<a href=".\faq.html">faq</a>                            
					</nav>
				</div>
			</div>
		</header>

		<!----------------->
		<!-- STUDY CARDS -->
		<!----------------->
		<section class="card-grid-container">
			<div class="card-grid">
				<!-- CARD 01-->
				<section class="card-grid-item db-locked-card">
					<a class="protocol-name" href="C:\Users\markw.consultant\_projects\BOS172722-01\profiles\output\patients-bos172722-01.html">
						<h3>BOS172722-01<br><div class="db-locked-text">DB Locked 2021-04-09</div></h3>
						<h3 class="nickname">MPS1</h3>
						<p>A Phase 1/1b Study of Paclitaxel in Combination with BOS172722, a Monopolar Spindle 1 Kinase Inhibitor, in Patients with Advanced Nonhaematologic Malignancies</p>
					</a>
				</section><!--

				CARD 02
				--><section class="card-grid-item db-locked-card">
					<a class="protocol-name" href="C:\Users\markw.consultant\_projects\BOS161721-02\profiles\output\patients-bos161721-02.html">
						<h3>BOS161721-02<br><div class="db-locked-text">DB Locked 2021-04-23</div></h3>
						<h3 class="nickname">Anti-IL21</h3>
						<p>A Randomized Double-blind Phase 1b/2 Combined Staggered Multiple Dose Escalation Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients On A Background of Limited Standard of Care</p>
					</a>
				</section><!--

				CARD 03
				--><section class="card-grid-item live-card">
					<a class="protocol-name" href="C:\Users\markw.consultant\_projects\BOS172738-01\profiles\output\patients-BOS172738-01.html">
						<h3>BOS172738-01</h3>
						<h3 class="nickname">RET</h3>
						<p>A Phase 1 Study of BOS172738 in Patients with Advanced Solid Tumors with RET Gene Alterations including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC)</p>
					</a>
				</section><!--

				CARD 04
				--><section class="card-grid-item db-locked-card">
					<a class="protocol-name" href="C:\Users\markw.consultant\_projects\BOS-356-101\profiles\output\patients-BOS-356-101.html">
						<h3>BOS-356-101<br><div class="db-locked-text">DB Locked 2021-02-16</div></h3>
						<h3 class="nickname">DGAT</h3>
						<p class="p-smaller">Phase 1, Randomized, Vehicle-controlled, Double-blind Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical Application of BOS-356 in Subjects with Moderate to Severe Acne Vulgaris</p>
					</a>
				</section><!--

				CARD 05
				--><section class="card-grid-item db-locked-card">
					<a class="protocol-name" href="C:\Users\markw.consultant\_projects\BOS-589-201\profiles\output\patients-bos-589-201.html">
						<h3>BOS-589-201<br><div class="db-locked-text">DB Locked 2020-11-18</div></h3>
						<h3 class="nickname">RET</h3>
						<p>A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients with Diarrhea-predominant IBS-D</p>
					</a>
				</section><!--

				CARD 06
				--><section class="card-grid-item live-card">
					<a class="protocol-name" href="C:\Users\markw.consultant\_projects\BOS-580-201\profiles\output\patients-bos-580-201.html">						
						<h3>BOS-580-201<br><div class="db-locked-text">Coming Soon</div></h3>
						<h3 class="nickname">FGF21</h3>
						<p>A 12-week Phase 2a randomized, blinded, placebo controlled study of BOS-580 in obese subjects at risk for nonalcoholic steatohepatitis (NASH)</p>
					</div>
				</section>
			</div>
		</section>

	</body>

</html>